Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01953679 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days
A Phase 2 study, sponsored by Premier Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT01953679 is a Phase 2 study that has completed, run by Premier Research. The registered enrollment target is 180 participants.
The verdict
NCT01953679, a Phase 2 study, has completed, sponsored by Premier Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
To compare the pharmacodynamic effects of 2 continuous dose regimens of ulipristal acetate 5.0 and 10.0 mg-only oral contraception, versus a 24/4 day regimen of UPA 5.0 mg.
Interventions
- DRUG Ulipristal Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01953679
The ClinicalTrials.gov registry entry for NCT01953679 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Premier Research, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ulipristal Acetate is the first listed.
NCT01953679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01953679 about?
NCT01953679 is a clinical study titled "Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days". To compare the pharmacodynamic effects of 2 continuous dose regimens of ulipristal acetate 5.0 and 10.0 mg-only oral contraception, versus a 24/4 day regimen of UPA 5.0 mg.
What is the current status of trial NCT01953679?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2014-03. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01953679?
The interventions under investigation include: Ulipristal Acetate (DRUG).
Who is sponsoring clinical trial NCT01953679?
This trial is sponsored by Premier Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.